ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/neurological
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Head & neck and Neurological / Neurological
39
trial(s) found.
NCT06926075
Advanced
Phase 1
Not yet recruiting
An Adaptive Phase I/II Study of Kesonotide, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours (
ADVICE
)
hGIIA-vimentin inhibitor
Breast cancer
Glioblastoma
Lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
NCT06838676
Paed
Phase 2
Not yet recruiting
A Phase II Trial of ACT001 in Children and Adolescents with Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas (
CONNECT2110
)
NFKB inhibitor
Diffuse intrinsic pontine glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT06413706
Paed
Phase 2
Recruiting
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
CDK4/6 inhibitor
alkylating agent
radiotherapy
Glioma
NSW
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT06395103
Paed
Phase 1 / Phase 2
Recruiting
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (
9999-01A
)
anti-ROR1 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
Burkitt lymphoma
Diffuse large B-cell lymphoma
Ewing sarcoma
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT06381570
Paed
Phase 0
Recruiting
VICTORY
: A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine With Oral Type II RAF Inhibitor Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
RAF inhibitor,type 2
vinca alkaloid
Low-grade glioma
NCT06333899
Paed
Phase 1
Not yet recruiting
A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion (
TarGeT-L
)
ALK inhibitor,third generation
ROS1 inhibitor
Anaplastic astrocytoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioblastoma
Glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT06326411
Advanced
Phase 1
Recruiting
A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue
NST-628
Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
pan-RAF/MEK glue
Glioma
Melanoma
NOT Melanoma
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06208657
Paed
Phase 1 / Phase 2
Recruiting
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (
OPTIMISE
)
Irinotecan
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Temozolomide
alkylating agent
cancer therapy
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
topoisomerase inhibitor
Cancer
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT06161974
Paed
Phase 2
Recruiting
Phase 2 Study of Olutasidenib with Temozolomide As Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations (
TarGeT-D
)
IDH1 R132 inhibitor
alkylating agent
Astrocytoma
Cancer
Central nervous system cancer
Diffuse intrinsic pontine glioma
Glioma
H3K27M-mutant glioma
High-grade glioma
Oligodendroglioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT06157541
Advanced
Phase 1 / Phase 2
Recruiting
Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme (
TCaP
)
anti-PD-1 monoclonal antibody
Astrocytoma
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
NA
NA
NCT05843253
Paed
Phase 2
Recruiting
PhaseII Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed With HGG Including DIPG, Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways (
CONNECT-TarGeT-A
)
CDK4/6 inhibitor
mTORC1 inhibitor
radiotherapy
Anaplastic astrocytoma
Central nervous system cancer
Diffuse intrinsic pontine glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05839379
Paed
Recruiting
Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma (
CONNECT-TarGeT-SCR
)
Anaplastic astrocytoma
Central nervous system cancer
Diffuse intrinsic pontine glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05577416
Advanced
Phase 1
Recruiting
A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma (
AB-218-IIT-201
)
IDH1 R132 inhibitor
Low-grade glioma
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
NCT05566795
Paed
Phase 3
Recruiting
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy (
DAY101-002
)
RAF inhibitor,type 2
Fibrosarcoma
Glioma
Low-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05503797
Advanced
Phase 2
Recruiting
A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations (
F8394-201
)
RAF dimer inhibitor
Cancer
Central nervous system cancer
Melanoma
NOT Colorectal adenocarcinoma
NOT Melanoma
NOT Non-small cell lung cancer
NOT Pancreatic adenocarcinoma
NOT Thyroid cancer
Solid tumour
Thyroid cancer
NSW
2031 - Randwick - Sydney Children's Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT05286801
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (
NCI-2022-01992
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
Atypical teratoid rhabdoid tumour
Carcinoma
Chordoma
Epithelioid sarcoma
Rhabdoid tumour
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT05270707
Radonc
Recruiting
HyperArc Registry Study (
VAR-2019-01
)
Radiotherapy
cancer therapy
Central nervous system cancer
ACT
2617 - Bruce - Icon Cancer Centre Canberra
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - ICON Cancer Care
4558 - Maroochydore - Icon Cancer Centre Maroochydore
NCT05230758
Paed
Phase 3
Recruiting
Phase III Randomized Double-blind Placebo-controlled Trial of Metformin for Cognitive Recovery and White Matter Growth in Paediatric Medulloblastoma Patients (
Met-Med-Can
)
biguanide antihyperglycaemic agent
placebo
Medulloblastoma
NSW
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (WITHDRAWN)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT04870944
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma (
PEPN2111
)
curaxin,FACT complex-targeting
Cancer
Central nervous system cancer
Diffuse intrinsic pontine glioma
H3K27M-mutant glioma
Lymphoma
Osteosarcoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
NCT04775485
Paed
Phase 2
Recruiting
FIREFLY-1
: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
RAF inhibitor,type 2
Low-grade glioma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT04774718
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available (
GO42286
)
ALK/RET inhibitor
ALK inhibitor,second generation
Central nervous system cancer
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
NCT04684368
Radonc
Phase 2
Recruiting
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (
ACNS2021
)
Carboplatin
Etoposide
Filgrastim
Ifosfamide
Mesna
Pegfilgrastim
Radiotherapy
Thiotepa
alkylating agent
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
sodium mercaptoethanesulfonate
topoisomerase inhibitor
Choriocarcinoma
Germ cell tumour
Germinoma
Mixed germ cell tumour
Teratoma
Testicular embryonal carcinoma
Yolk sac tumour
NSW
2031 - Randwick - Sydney Children's Hospital (SUSPENDED)
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne (SUSPENDED)
QLD
4101 - South Brisbane - Queensland Children's Hospital (SUSPENDED)
WA
6009 - Perth - Perth Children's Hospital (SUSPENDED)
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04655404
Paed
Phase 1
Recruiting
A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion (
CONNECT1903
)
TRK inhibitor,first generation
Diffuse intrinsic pontine glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT04323046
Paed
Phase 1
Recruiting
A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)
Nivolumab
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,PD-1-targeting
Glioblastoma
Glioma
Malignant glioma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT04221035
Radonc
Phase 3
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (
HR-NBL2
)
Busulfan
Carboplatin
Cisplatin
Cyclophosphamide
Dacarbazine
Dinutuximab
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Melphalan
Radiotherapy
Temozolomide
Thiotepa
Vincristine
alkylating agent
anthracycline
anti-GD2 monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
WA
6009 - Perth - Perth Children's Hospital (SUSPENDED)
NCT04094610
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations (
CA127-1029
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Central nervous system cancer
Lymphoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT03970447
Radonc
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
Troriluzole
VAL-083
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
glutamate modulator
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NCT03838042
Paed
Phase 1 / Phase 2
Recruiting
INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt) (
Final4,-18-10-2023
)
HDAC inhibitor,class 1 selective
anti-PD-1 monoclonal antibody
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
WA
6009 - Perth - Perth Children's Hospital
NCT03175224
Advanced
Phase 2
Recruiting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (
SPARTA
)
MET inhibitor,type 1
Cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Glioblastoma
Kidney cancer
Lung cancer
MET:alteration
MET:fusion
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
Thyroid cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
ACTRN12624001484538
Advanced
Phase 2
Not yet recruiting
Phase 2 Trial examining IMMUNE-12 for patients with Glioblastoma Multiforme (GBM). (
GBMI12
)
Ifosfamide
Radiotherapy
Temozolomide
alkylating agent
cancer therapy
cytotoxic chemotherapy
Glioblastoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4120 - Greenslopes - Greenslopes Private Hospital
ACTRN12623001126606
Advanced
Phase 1 / Phase 2
Recruiting
Phase I/II clinical trial evaluating the safety and efficacy of allogeneic cytomegalovirus-specific T cells in combination with pembrolizumab for recurrent and newly diagnosed glioblastoma multiforme (
TCaP
)
anti-PD-1 monoclonal antibody
Astrocytoma
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12623000104651
Paed
Phase 1
Recruiting
Phase I Trial of the Safety and Efficacy of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours (
DART
)
Fluorouracil
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Ependymoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622001514796
Advanced
Not Applicable
Recruiting
KARPOS
- A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme
Bevacizumab
CAR-T-cell therapy
CAR-T-cell therapy,GD2-targeting
Cyclophosphamide
Fludarabine
GD2-iCAR-PBT
Ifosfamide
alkylating agent
anti-VEGF monoclonal antibody
antimetabolite
autologous CAR-T-cell therapy
autologous CAR-T-cell therapy,GD2-targeting
cancer therapy
cancer therapy,GD2-targeting
cancer therapy,VEGF-targeting
cell therapy
cytotoxic chemotherapy
immuno-oncology therapy,VEGF-targeting
Glioblastoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12622001201763
Advanced
Phase 2
Recruiting
Efficacy of Treatment Targeting the Renin-Angiotensin System in Glioblastoma (
TRAS-GB
) Trial
COX2 inhibitor
Celecoxib
Metformin
Propranolol
Radiotherapy
Temozolomide
alkylating agent
antihypertensives
beta-adrenergic blocker
biguanide antihyperglycaemic agent
cancer therapy
cancer therapy,COX2-targeting
cytotoxic chemotherapy
Glioblastoma
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
ACTRN12622000675729
Paed
Not Applicable
Recruiting
A Phase I Study of the Safety of Autologous GD2-Specific Chimeric Antigen Receptor-Expressing T Cells in Children with Diffuse Midline Glioma (
LEVI’S-CATCH
)
Bevacizumab
CAR-T-cell therapy
CAR-T-cell therapy,GD2-targeting
Cyclophosphamide
Fludarabine
GD2-iCAR-PBT
Radiotherapy
alkylating agent
anti-VEGF monoclonal antibody
antimetabolite
autologous CAR-T-cell therapy
autologous CAR-T-cell therapy,GD2-targeting
cancer therapy
cancer therapy,GD2-targeting
cancer therapy,VEGF-targeting
cell therapy
cytotoxic chemotherapy
immuno-oncology therapy,VEGF-targeting
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
High-grade glioma
NSW
2031 - Randwick - Prince of Wales Hospital
ACTRN12620001229965
Paed
Phase 2
Recruiting
A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas (
TiNT
)
MEK inhibitor
Glioma
Neurofibromatosis
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
ACTRN12614000552684
Paed
Phase 1
Not yet recruiting
A Phase 1 study of Temozolomide, Irinotecan, and O6BG (O6-Benzylguanine) for Children with Recurrent or Resistant Neuroblastoma (
The-TIO-Study
)
alkylating agent
topoisomerase inhibitor
Neuroblastoma
NCT05450744
Advanced
Phase 1
Unknown
A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma (
IPAX-2
)
131I-IPA
131I-TLX-101
cancer therapy
cancer therapy,LAT1-targeting
cancer therapy,LAT2-targeting
radioiodine conjugate
radioiodine therapy
radioligand,LAT1/LAT2-targeting
radiopharmaceutics
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (33)
Not yet recruiting (5)
Unknown (1)
Recruitment Country and State
NSW (27)
QLD (24)
VIC (21)
WA (17)
SA (10)
NZ (5)
TAS (2)
ACT (1)
Phase
Phase 0 (1)
Phase 1 (9)
Phase 1 / Phase 2 (9)
Phase 2 (12)
Phase 2 / Phase 3 (1)
Phase 3 (3)
Trial Type
Paed (22)
Advanced (13)
Radonc (4)
Paed (1)
Cancer Therapy Class
PD-1/PD-L1
15%
BRAF
13%
RAF
13%
PD-1
13%
CRAF
10%
pan-RAF
10%
mTOR
10%
mTORC1
10%
ALK
8%
PI3K
8%
PI3K delta
8%
PI3Kalpha
8%
mTORC2
8%
GD2
8%
CDK4
5%
CDK6
5%
ROS1
5%
MEK
5%
IDH1
5%
IDH1 R132
5%
RET
5%
TRK
5%
VEGF
5%
hGIIA-vimentin
3%
NFKB
3%
ROR1
3%
DPD
3%
orotate phosphoribosyltransferase
3%
PD-L1
3%
TIGIT
3%
FACT complex
3%
FGFR
3%
FGFR1
3%
FGFR1/2/3
3%
FGFR2
3%
FGFR3
3%
FGFR4
3%
KIT
3%
PDGFR
3%
VEGFR
3%
HDAC
3%
MET
3%
CTLA4
3%
PARP
3%
XPO1
3%
COX2
3%
LAT1
3%
LAT2
3%
Facility
2031 - Randwick - Sydney Children's Hospital (19)
6009 - Perth - Perth Children's Hospital (16)
4101 - South Brisbane - Queensland Children's Hospital (15)
2145 - Westmead - The Children's Hospital at Westmead (10)
3052 - Parkville - Royal Children's Hospital Melbourne (10)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (4)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (3)
4120 - Greenslopes - Greenslopes Private Hospital (3)
2305 - New Lambton Heights - John Hunter Children's Hospital (3)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
2031 - Randwick - Prince of Wales Hospital (3)
3168 - Clayton - Monash Medical Centre (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
3168 - Clayton - Monash Children's Hospital (2)
NZ.1023 - Grafton - Starship Children's Hospital (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (2)
7000 - Hobart - Royal Hobart Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
NA
2305 - New Lambton Heights - Newcastle Private Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
2617 - Bruce - Icon Cancer Centre Canberra (1)
4215 - Southport - ICON Cancer Care (1)
4558 - Maroochydore - Icon Cancer Centre Maroochydore (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2170 - Liverpool - Liverpool Hospital (1)
3066 - Epping - Northern Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre (1)
Cancer Type
Cancer
Neurological cancer
Solid tumour
Central nervous system cancer
Glioma
Malignant glioma
High-grade glioma
Glioblastoma
Diffuse intrinsic pontine glioma
H3K27M-mutant glioma
Low-grade glioma
Sarcoma
Anaplastic astrocytoma
Lung cancer
Respiratory tract cancer
Thoracic cancer
Urogenital cancer
Bone cancer
Ewing family of tumours
Haematological malignancy
Lymphoma
Neuroblastic tumour
Neuroblastoma
Peripheral nervous system tumour
Diffuse midline glioma
Astrocytoma
Gastrointestinal cancer
Male genital cancers
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Melanoma
Non-small cell lung cancer
Endocrine gland cancer
Thyroid cancer
Central nervous system primitive neuroectodermal tumour
Breast cancer
Gynaecological cancer
Ovarian cancer
Prostate cancer
Skin cancer
Acute lymphoblastic leukaemia
B-cell acute lymphoblastic leukaemia/lymphoma
B-cell lymphoma
B-cell malignancy
Burkitt lymphoma
Diffuse large B-cell lymphoma
Ewing sarcoma
High-grade B-cell lymphoma
Leukaemia
Lymphoid leukaemia
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Primitive neuroectodermal tumour
Oligodendroglioma
Fibrosarcoma
Atypical teratoid rhabdoid tumour
Carcinoma
Chordoma
Epithelioid sarcoma
Rhabdoid tumour
Soft tissue sarcoma
Medulloblastoma
Osteosarcoma
Choriocarcinoma
Germ cell tumour
Germinoma
Mixed germ cell tumour
Non-seminoma
Teratoma
Testicular cancer
Testicular embryonal carcinoma
Yolk sac tumour
Colon adenocarcinoma
Colorectal adenocarcinoma
Colorectal cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Kidney cancer
Lower gastrointestinal cancer
MET:alteration
MET:fusion
Oesophageal cancer
Ependymoma
Neurofibromatosis
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy